Xeno Pharmaaceuticals Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
as on 10-07-2024
- Paid Up Capital ₹ 4.00 M
as on 10-07-2024
- Company Age 15 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.00 Cr
as on 10-07-2024
- Satisfied Charges ₹ 1.50 Cr
as on 10-07-2024
- Revenue -8.07%
(FY 2020)
- Profit -35.75%
(FY 2020)
- Ebitda -17.61%
(FY 2020)
- Net Worth 3.83%
(FY 2020)
- Total Assets -4.84%
(FY 2020)
About Xeno Pharmaaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 4.00 M.
The company currently has active open charges totaling ₹2.00 Cr. The company has closed loans amounting to ₹1.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
Palani Sakthivel and Muthukrishnan Mahendrakumar serve as directors at the Company.
- CIN/LLPIN
U33112TN2009PTC071160
- Company No.
071160
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Mar 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Tiruvallur, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Xeno Pharmaaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Palani Sakthivel  | Managing Director | 27-Mar-2009 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Muthukrishnan Mahendrakumar | Director | 27-Mar-2009 | Current |
Financial Performance of Xeno Pharmaaceuticals.
Xeno Pharmaaceuticals Private Limited, for the financial year ended 2020, experienced Minor drop in revenue, with a 8.07% decrease. The company also saw a substantial fall in profitability, with a 35.75% decrease in profit. The company's net worth moved up by a moderate rise of 3.83%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Xeno Pharmaaceuticals?
In 2020, Xeno Pharmaaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Onex Life Science Private LimitedActive 15 years 7 monthsPalani Sakthivel and Muthukrishnan Mahendrakumar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 22 Jun 2021 | ₹1.00 Cr | Open |
Others Creation Date: 07 Jun 2021 | ₹1.00 Cr | Open |
Others Creation Date: 27 Jun 2016 | ₹1.50 Cr | Satisfied |
How Many Employees Work at Xeno Pharmaaceuticals?
Xeno Pharmaaceuticals has a workforce of 8 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Xeno Pharmaaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Xeno Pharmaaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
